ClearPoint Neuro (Nasdaq:CLPT) announced that it completed the first procedures with its laser therapy and navigation systems.
In September 2022, the FDA cleared the company’s Swedish partner Clinical Laserthermia Systems’ neuro laser therapy system. The Solana Beach, California-based company planned from then to commercialize the system as the Prism.
ClearPoint Neuro holds exclusive global rights to commercialize the CLS magnetic resonance (MR) guided laser interstitial thermal therapy (MRgLITT) system for neuro applications.
Dr. Jonathan Riley and a team at Kaleida Health in Buffalo, New York, completed the procedure.
“We are ecstatic to have completed our first successful case with combined ClearPoint Neuro MRI targeting and laser ablation solutions,” Riley said. “This is a world-leading suite of technologies that allows us to offer selected minimally invasive neurosurgical procedures to patients in our region.”
The Prism system features the only non-cooled laser applicator on the market, the company said. Its next-generation laser applicator technology eliminates the need for external cooling. This simplifies setup, reduces power and ablation time and lessens imaging artifact for more efficient workflows.
ClearPoint Neuro currently has the Prism laser in a limited market release at select academic medical centers in the U.S.
“Our successful first case with Dr. Riley and the team at Kaleida Health is emblematic of the excellent collaboration we have both with our customers and within our organization,” said Chris Osswald, segment leader for laser therapy at ClearPoint Neuro. “Our limited market release has been such a positive experience, mainly because of our team’s dedication. We look forward to continued success together with the team at Kaleida Health and as we look to expand into full market release later this year.”